Skip to main navigation Skip to search Skip to main content

Multiplex lateral flow test sensitivity and specificity in detecting influenza A, B and SARS-CoV-2 in adult patients in a UK emergency department

  • Rahul Batra
  • , Edward Blandford
  • , Raghavendran Kulasegaran-Shylini
  • , Matthias E Futschik
  • , Abbie Bown
  • , Matthew Catton
  • , Hermione Conti-Frith
  • , Alexandra Alexandridou
  • , Rebecca Gill
  • , Clara Milroy
  • , Sean Harper
  • , Holly Gettings
  • , Maryann Noronha
  • , Hooi-Ling Harrison
  • , Sam Douthwaite
  • , Gaia Nebbia
  • , Paul E Klapper
  • , Sarah Tunkel
  • , Richard Vipond
  • , Susan Hopkins
  • Tom Fowler
  • St Thomas' Hospital
  • Science Group, UK Health Security Agency, London, UK.
  • UK Health Security Agency Porton, Salisbury, UK.
  • Emergency Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • University of Manchester
  • Queen Mary University of London

Research output: Contribution to journalArticlepeer-review

3 Downloads (Pure)

Abstract

BACKGROUND: Rapid identification of individuals with acute respiratory infections is crucial for preventing nosocomial infections. For rapid diagnosis, especially in EDs, lateral flow devices (LFDs) are a convenient, inexpensive option with a rapid turnaround. Several 'multiplex' LFDs (M-LFDs) now exist, testing for multiple pathogens from a single swab sample. We evaluated the real-world performance of M-LFD versus PCR testing in detecting influenza A, B and SARS-CoV-2) in the ED setting.

METHODS: After preliminary evaluation of an M-LFD (SureScreen) with laboratory-grown virus and PCR-negative clinical samples, it was evaluated in a real-world setting at the ED of St Thomas' Hospital (London, UK) from 1 December 2022 to 21 April 2023. Eligible participants were ≥18 years of age, admitted with respiratory symptoms and received concurrent M-LFD and PCR tests. Main endpoints were sensitivity to detect influenza A/B (primary) and SARS-CoV-2 (secondary) versus PCR. The probability of a true positive in relation to viral concentration (expressed as PCR cycle threshold (Ct)) was analysed using logistic regression.

RESULTS: In total, 808 symptomatic participants were included (49.8% female; mean age 46.9 years). Test sensitivity (95% CI) was 67.0% (56.9% to 76.1%) for influenza A (n=100), 94.1% (71.3% to 99.9%) for influenza B (n=17) and 48.2% (39.7% to 56.8%) for SARS-CoV-2 (n=141). Sensitivity for SARS-CoV-2 was significantly lower than that for influenza A and B (p=0.0057 and p=0.00088, respectively). The probability of a true positive was 98% for Ct<25 for influenza A and SARS-CoV-2 (influenza B non-evaluable). No co-infections were identified by PCR or M-LFD.

CONCLUSION: The real-world performance of SureScreen M-LFD was consistent with laboratory evaluation and achieved a high sensitivity for individuals with high viral concentration, most likely to be infectious. Given the representative UK population sample, results could be generalised for use in other settings.

Original languageEnglish
Pages (from-to)98-104
Number of pages7
JournalEmerg Med J
Volume42
Issue number2
Early online date14 Jan 2025
DOIs
Publication statusPublished - Feb 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Humans
  • Influenza, Human/diagnosis
  • Female
  • Emergency Service, Hospital/organization & administration
  • Male
  • Sensitivity and Specificity
  • Middle Aged
  • COVID-19/diagnosis
  • SARS-CoV-2/isolation & purification
  • United Kingdom
  • Adult
  • Influenza B virus/isolation & purification
  • Influenza A virus/isolation & purification
  • Aged

Fingerprint

Dive into the research topics of 'Multiplex lateral flow test sensitivity and specificity in detecting influenza A, B and SARS-CoV-2 in adult patients in a UK emergency department'. Together they form a unique fingerprint.

Cite this